Novartis AG ADR (NVS)vsViemed Healthcare Inc (VMD)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
VMD
Viemed Healthcare Inc
$8.79
+0.46%
HEALTHCARE · Cap: $345.84M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 18697% more annual revenue ($56.69B vs $301.61M). NVS leads profitability with a 22.5% profit margin vs 4.8%. VMD appears more attractively valued with a PEG of 1.86. VMD earns a higher WallStSmart Score of 52/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VMD
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
+27.3%
Fair Value
$11.62
Current Price
$8.79
$2.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 23.9% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Expensive relative to growth rate
Moderate valuation
Smaller company, higher risk/reward
4.8% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : VMD
The strongest argument for VMD centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 23.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : VMD
The primary concerns for VMD are PEG Ratio, P/E Ratio, Market Cap. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a value stock while VMD is a growth play — different risk/reward profiles.
VMD carries more volatility with a beta of 1.09 — expect wider price swings.
VMD is growing revenue faster at 23.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
VMD scores higher overall (52/100 vs 51/100) and 23.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Viemed Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?